Kedudukan dalam Saham
#41419
Diagnocure, Inc. is a Canadian life sciences company dedicated to developing... Diagnocure, Inc. is a Canadian life sciences company dedicated to developing and commercializing innovative products for cancer diagnosis. Its core business revolves around advanced molecular diagnostic tests designed for the identification and management of cancerous conditions. The company's portfolio includes the PCA3 test for prostate cancer diagnosis, as well as the Guanylyl Cyclase C (GCC) marker and the Previstage GCC colorectal cancer staging test, both vital for patients with colorectal cancer. They also offer PCP, a multi-marker diagnostic for prostate cancer. In addition to these tests, Diagnocure provides specialized services such as gene expression and copy number variation analysis, mutation detection, SNP genotyping, and comprehensive platform and laboratory environmental support. Established in 1994 as 9342-8530 Québec Inc. and previously known as DiagnoCure Inc., the company is headquartered in Quebec, Canada.
Harga Saham
$0.0001
Disegerakkan terakhir: 2025-06-11
Perubahan (1 tahun)
0.00%
Perdagangan Diagnocure, Inc. (DGCRF)
Harga DGCRF dengan permodalan pasaran b
Modal pasaran bagi Diagnocure, Inc.(DGCRF)
Modal Pasaran: $21.52K
Sehingga August 2026, Diagnocure, Inc. mempunyai modal pasaran sebanyak $21.52K. Ini menjadikan Diagnocure, Inc. syarikat ke-41419th paling bernilai di dunia mengikut data kami. Kapitalisasi pasaran ialah nilai keseluruhan saham syarikat tersenarai yang berada dalam edaran dan lazimnya digunakan untuk menilai nilai syarikat tersebut.
Sejarah modal pasaran Diagnocure, Inc. dari 2012 hingga 2026
DGCRF berbanding dengan 5 teratas yang paling popular stocks
| Harga DGCRF |
|
Aset B |
Pasaran B |
Hasilnya |
|
|
|
|
$5.383T
|
+25,015,610,773.61%
|
|
|
|
|
$4.423T
|
+20,554,791,738.93%
|
|
|
|
|
$4.160T
|
+19,332,571,457.07%
|
|
|
|
|
$3.663T
|
+17,022,866,242.94%
|
|
|
|
|
$2.891T
|
+13,435,077,945.54%
|
